Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer

Molecular Therapy

Volumn 20, Issue 2, 2012, Pages 347-355

  Hine, Christopher M ^a,b   Seluanov, Andrei ^a   Gorbunova, Vera ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXIN; DIPHTHERIA TOXIN A; LUCIFERASE; NANOPARTICLE; POLYETHYLENEIMINE; RAD51 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; BIOLUMINESCENCE; CANCER INHIBITION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE CONSTRUCT; HELA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEUM TUMOR; PROMOTER REGION; SUBCUTANEOUS TISSUE TUMOR; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

MUS;

EID: 84856542964     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.215     Document Type: Article

References (50)

1. Baumann, P and West, SC (1998). Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 23: 247-251. (Pubitemid 28343368)
2. Petermann, E, Orta, ML, Issaeva, N, Schultz, N and Helleday, T (2010). Hydroxyureastalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell 37: 492-502.
3. Hine, CM, Seluanov, A and Gorbunova, V (2008). Use of the Rad51 promoter for targeted anti-cancer therapy. Proc Natl Acad Sci USA 105: 20810-20815.
4. Richardson, C (2005). RAD51, genomic stability, and tumorigenesis. Cancer Lett 218: 127-139. (Pubitemid 40164714)
5. Miyagawa, K (2008). Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Sci 99: 187-194. (Pubitemid 351228469)
6. Raderschall, E, Stout, K, Freier, S, Suckow, V, Schweiger, S and Haaf, T (2002). Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 62: 219-225. (Pubitemid 34074008)
7. Maacke, H, Jost, K, Opitz, S, Miska, S, Yuan, Y, Hasselbach, L et al. (2000). DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 19: 2791-2795. (Pubitemid 30339230)
8. Xia, SJ, Shammas, MA and Shmookler Reis, RJ (1997). Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol Cell Biol 17: 7151-7158. (Pubitemid 27505945)
9. Haram, KM, Peltier, HJ, Lu, B, Bhasin, M, Otu, HH, Choy, B et al. (2008). Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Prostate 68: 1517-1530.
10. Schild, D and Wiese, C (2010). Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res 38: 1061-1070.
11. Collis, SJ, Tighe, A, Scott, SD, Roberts, SA, Hendry, JH and Margison, GP (2001). Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 29: 1534-1538. (Pubitemid 32288501)
12. Hannay, JA, Liu, J, Zhu, QS, Bolshakov, SV, Li, L, Pisters, PW et al. (2007). Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther 6: 1650-1660. (Pubitemid 46954032)
13. Mitra, A, Jameson, C, Barbachano, Y, Sanchez, L, Kote-Jarai, Z, Peock, S et al.; IMPACT Steering Committee and IMPACT and EMBRACE Collaborators. (2009). Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 55: 696-704.
14. Maacke, H, Opitz, S, Jost, K, Hamdorf, W, Henning, W, Krüger, S et al. (2000). Overexpression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer 88: 907-913.
15. Qiao, GB, Wu, YL, Yang, XN, Zhong, WZ, Xie, D, Guan, XY et al. (2005). High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer 93: 137-143. (Pubitemid 41076262)
16. Nogueira, A, Catarino, R, Coelho, A, Araujo, A, Gomes, M and Medeiros, R (2009). Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy. Cancer Chemother Pharmacol 66(3): 501-506.
17. Russell, JS, Brady, K, Burgan, WE, Cerra, MA, Oswald, KA, Camphausen, K et al. (2003). Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 63: 7377-7383. (Pubitemid 37413479)
18. Ohnishi, T, Taki, T, Hiraga, S, Arita, N and Morita, T (1998). In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun 245: 319-324. (Pubitemid 28418498)
19. Du, LQ, Wang, Y, Wang, H, Cao, J, Liu, Q and Fan, FY (2010). Knockdown of Rad51 expression induces radiation-and chemo-sensitivity in osteosarcoma cells. Med Oncol (epub ahead of print).
20. Hardcastle, J, Kurozumi, K, Chiocca, EA and Kaur, B (2007). Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets 7: 181-189. (Pubitemid 46348633)
21. Wu, L, Johnson, M and Sato, M (2003). Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol Med 9: 421-429. (Pubitemid 37309643)
22. Lo, HW, Day, CP and Hung, MC (2005). Cancer-specific gene therapy. Adv Genet 54: 235-255.
23. Abdul-Ghani, R, Ohana, P, Matouk, I, Ayesh, S, Ayesh, B, Laster, M et al. (2000). Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2: 539-544.
24. Koga, S, Hirohata, S, Kondo, Y, Komata, T, Takakura, M, Inoue, M et al. (2000). A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 11: 1397-1406. (Pubitemid 30451020)
25. Gu, J and Fang, B (2003). Telomerase promoter-driven cancer gene therapy. Cancer Biol Ther 2(4 Suppl 1): S64-S70.
26. Huang, YH, Zugates, GT, Peng, W, Holtz, D, Dunton, C, Green, JJ et al. (2009). Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice. Cancer Res 69: 6184-6191.
27. Latham, JP, Searle, PF, Mautner, V and James, ND (2000). Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 60: 334-341. (Pubitemid 30070760)
28. Peng, W, Chen, J, Huang, YH and Sawicki, JA (2005). Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells. Gene Ther 12: 1573-1580. (Pubitemid 41541775)
29. Showalter, SL, Huang, YH, Witkiewicz, A, Costantino, CL, Yeo, CJ, Green, JJ et al. (2008). Nanoparticulate delivery of diphtheria toxin DNA effectively kills mesothelin expressing pancreatic cancer cells. Cancer Biol Ther 7: 1584-1590.
30. Hassan, R and Ho, M (2008). Mesothelin targeted cancer immunotherapy. Eur J Cancer 44: 46-53. (Pubitemid 350262830)
31. Breidenbach, M, Rein, DT, Everts, M, Glasgow, JN, Wang, M, Passineau, MJ et al. (2005). Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther 12: 187-193. (Pubitemid 40185922)
32. Yamaizumi, M, Mekada, E, Uchida, T and Okada, Y (1978). One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15: 245-250. (Pubitemid 9027527)
33. Chang, MP, Bramhall, J, Graves, S, Bonavida, B and Wisnieski, BJ (1989). Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J Biol Chem 264: 15261-15267. (Pubitemid 19242889)
34. Ohana P, Schacter, P, Ayesh, B, Mizrahi, A, Ayesh, S, Birman, Tet al. (2004). The use of the regulatory sequences of H19 and IGF2 genes in DNA based therapy of colorectal rat liver metastases. Molecular Therapy 9: S107-S108.
35. Vernejoul, F, Faure, P, Benali, N, Calise, D, Tiraby, G, Pradayrol, L et al. (2002). Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 62: 6124-6131. (Pubitemid 35244461)
36. Boussif, O, Lezoualc'h, F, Zanta, MA, Mergny, MD, Scherman, D, Demeneix, B et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92: 7297-7301.
37. Ohana, P, Gofrit, O, Ayesh, S, Al-Sharef, W, Mizrahi, A, Birman, T et al. (2004). Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer. Gene Ther Mol Biol 8: 181-192.
38. Kobayashi, M, Kikuchi, D and Okamura, H (2009). Imaging of ultraweak spontaneous photon emission from human body displaying diurnal rhythm. PLoS ONE 4: e6256.
39. Kang, JH and Chung, JK (2008). Molecular-genetic imaging based on reporter gene expression. J Nucl Med 49 Suppl 2: 164S-179S.
40. Liang, S, Mele, J, Wu, Y, Buffenstein, R and Hornsby, PJ (2010). Resistance to experimental tumorigenesis in cells of a long-lived mammal, the naked mole-rat (Heterocephalus glaber). Aging Cell 9: 626-635.
41. Herschman, HR (2004). PET reporter genes for noninvasive imaging of gene therapy, cell tracking and transgenic analysis. Crit Rev Oncol Hematol 51: 191-204. (Pubitemid 39158688)
42. Anderson, DG, Peng, W, Akinc, A, Hossain, N, Kohn, A, Padera, R et al. (2004). A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci USA 101: 16028-16033. (Pubitemid 39507921)
43. Jin, S and Ye, K (2007). Nanoparticle-mediated drug delivery and gene therapy. Biotechnol Prog 23: 32-41. (Pubitemid 46293483)
44. Xu, Z, Shen, G, Xia, X, Zhao, X, Zhang, P, Wu, H et al. (2011). Comparisons of three polyethyleneimine-derived nanoparticles as a gene therapy delivery system for renal cell carcinoma. J Transl Med 9: 46.
45. Garrison, RN, Kaelin, LD, Galloway, RH and Heuser, LS (1986). Malignant ascites. Clinical and experimental observations. Ann Surg 203: 644-651. (Pubitemid 16062481)
46. Armstrong, DK, Bundy, B, Wenzel, L, Huang, HQ, Baergen, R, Lele, S et al.; Gynecologic Oncology Group. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43. (Pubitemid 43048949)
47. Ferrari, M (2005). Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5: 161-171. (Pubitemid 40314948)
48. Peng, W, Anderson, DG, Bao, Y, Padera, RF Jr, Langer, R and Sawicki, JA (2007). Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors. Prostate 67: 855-862. (Pubitemid 46828939)
49. Han, H, Bearss, DJ, Browne, LW, Calaluce, R, Nagle, RB and Von Hoff, DD (2002). Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 62: 2890-2896. (Pubitemid 34525776)
50. Jewell, R, Conway, C, Mitra, A, Randerson-Moor, J, Lobo, S, Nsengimana, J et al. (2010). Patterns of expression of DNA repair genes and relapse from melanoma. Clin Cancer Res 16: 5211-5221.